The Swiss group's CEO declined to comment when asked about any takeover interest in ADC specialist Seagen Inc which, according to a Wall Street Journal report last week, has attracted Merck & Co and other rival drugmakers as potential suitors.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/0eOKDCR
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» Roche sceptical about investing more in 'guided-missile' ADC cancer drugs
https://ift.tt/KPd7b2s
No comments:
Post a Comment